"Leukemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Descriptor ID |
D007938
|
MeSH Number(s) |
C04.557.337
|
Concept/Terms |
Leukemia- Leukemia
- Leukemias
- Leucocythaemia
- Leucocythaemias
- Leucocythemia
- Leucocythemias
|
Below are MeSH descriptors whose meaning is more general than "Leukemia".
Below are MeSH descriptors whose meaning is more specific than "Leukemia".
This graph shows the total number of publications written about "Leukemia" by people in this website by year, and whether "Leukemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 5 | 0 | 5 |
1995 | 6 | 3 | 9 |
1996 | 10 | 0 | 10 |
1997 | 3 | 1 | 4 |
1998 | 2 | 2 | 4 |
1999 | 6 | 1 | 7 |
2000 | 5 | 1 | 6 |
2001 | 3 | 0 | 3 |
2002 | 3 | 3 | 6 |
2003 | 5 | 0 | 5 |
2004 | 1 | 3 | 4 |
2005 | 0 | 4 | 4 |
2006 | 5 | 5 | 10 |
2007 | 2 | 2 | 4 |
2008 | 5 | 2 | 7 |
2009 | 3 | 5 | 8 |
2010 | 6 | 3 | 9 |
2011 | 2 | 3 | 5 |
2012 | 3 | 1 | 4 |
2013 | 6 | 2 | 8 |
2014 | 5 | 0 | 5 |
2015 | 3 | 0 | 3 |
2016 | 3 | 0 | 3 |
2017 | 6 | 1 | 7 |
2018 | 4 | 1 | 5 |
2019 | 3 | 0 | 3 |
2020 | 2 | 1 | 3 |
2021 | 3 | 3 | 6 |
2022 | 9 | 0 | 9 |
2023 | 6 | 0 | 6 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia" by people in Profiles.
-
RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis. Nature. 2024 Oct; 634(8035):986-994.
-
Late subsequent leukemia after childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). Cancer Med. 2024 Oct; 13(20):e70086.
-
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 Apr 08; 42(4):552-567.e6.
-
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024 04 01; 109(4):1046-1052.
-
Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017. Cancer. 2024 03 01; 130(5):750-769.
-
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107.
-
Automated Matching of Patients to Clinical Trials: A Patient-Centric Natural Language Processing Approach for Pediatric Leukemia. JCO Clin Cancer Inform. 2023 07; 7:e2300009.
-
The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023 08; 98(8):1286-1306.
-
The International Consensus Classification of acute leukemias of ambiguous lineage. Blood. 2023 05 04; 141(18):2275-2277.
-
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer J. 2023 03 23; 13(1):42.